WO2018159990A3 - Complexe de nanoparticules d'or marqué à l'alendronate thiolé, procédé de fabrication associé et application associée - Google Patents

Complexe de nanoparticules d'or marqué à l'alendronate thiolé, procédé de fabrication associé et application associée Download PDF

Info

Publication number
WO2018159990A3
WO2018159990A3 PCT/KR2018/002433 KR2018002433W WO2018159990A3 WO 2018159990 A3 WO2018159990 A3 WO 2018159990A3 KR 2018002433 W KR2018002433 W KR 2018002433W WO 2018159990 A3 WO2018159990 A3 WO 2018159990A3
Authority
WO
WIPO (PCT)
Prior art keywords
gold nanoparticle
alendronate
thiolated
application
method therefor
Prior art date
Application number
PCT/KR2018/002433
Other languages
English (en)
Korean (ko)
Other versions
WO2018159990A2 (fr
Inventor
최원일
태기융
사후아비식
Original Assignee
한국세라믹기술원
광주과학기술원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국세라믹기술원, 광주과학기술원 filed Critical 한국세라믹기술원
Publication of WO2018159990A2 publication Critical patent/WO2018159990A2/fr
Publication of WO2018159990A3 publication Critical patent/WO2018159990A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un complexe de nanoparticules d'or ayant un alendronate marqué à sa surface, le complexe de nanoparticules d'or comprenant : une nanoparticule d'or et un alendronate fixé à la surface de la nanoparticule d'or par un lieur comprenant un groupe sulfhydryle. La présente invention, comme décrit ci-dessus, concerne un complexe dans lequel une nanoparticule d'or a un groupe alendronate lié à sa surface par l'intermédiaire d'un lieur comprenant un groupe sulfhydryle, ce qui permet d'obtenir un complexe qui est stable par rapport à des concentrations d'ions calcium et capable de quantifier avec précision des concentrations d'ions calcium.
PCT/KR2018/002433 2017-02-28 2018-02-28 Complexe de nanoparticules d'or marqué à l'alendronate thiolé, procédé de fabrication associé et application associée WO2018159990A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0026042 2017-02-28
KR1020170026042A KR101992401B1 (ko) 2017-02-28 2017-02-28 티올레이트 알렌드로네이트가 표지된 금나노입자 복합체 및 이의 제조방법, 이의 응용

Publications (2)

Publication Number Publication Date
WO2018159990A2 WO2018159990A2 (fr) 2018-09-07
WO2018159990A3 true WO2018159990A3 (fr) 2019-01-10

Family

ID=63370715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/002433 WO2018159990A2 (fr) 2017-02-28 2018-02-28 Complexe de nanoparticules d'or marqué à l'alendronate thiolé, procédé de fabrication associé et application associée

Country Status (2)

Country Link
KR (1) KR101992401B1 (fr)
WO (1) WO2018159990A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098574A1 (en) * 2006-04-25 2009-04-16 Centre National De La Recherche Scientifique (Cnrs) Functionalization of gold nanoparticles with oriented proteins, application to the high-density labelling of cell membranes
US20160058892A1 (en) * 2013-04-04 2016-03-03 The Governors Of The University Of Alberta Preparation of bone-seeking superparamagnetic iron nanoparticles as contrast agents and methods for using the same
KR20160115571A (ko) * 2015-03-27 2016-10-06 경희대학교 산학협력단 알렌드로네이트 결합 금나노입자

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101680786B1 (ko) * 2016-07-29 2016-11-29 경북대학교 산학협력단 골 재생용 생체 재료 및 이의 제조 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098574A1 (en) * 2006-04-25 2009-04-16 Centre National De La Recherche Scientifique (Cnrs) Functionalization of gold nanoparticles with oriented proteins, application to the high-density labelling of cell membranes
US20160058892A1 (en) * 2013-04-04 2016-03-03 The Governors Of The University Of Alberta Preparation of bone-seeking superparamagnetic iron nanoparticles as contrast agents and methods for using the same
KR20160115571A (ko) * 2015-03-27 2016-10-06 경희대학교 산학협력단 알렌드로네이트 결합 금나노입자

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GHOSH, SOUMITRA S. ET AL.: "Use of Maleimide-thiol Coupling Chemistry for Efficient Syntheses of Oligonucleotide-enzyme Conjugate Hybridization Probes", BIOCONJUGATE CHEMISTRY, vol. 1, no. 1, 1990, pages 71 - 76, XP002131636, DOI: doi:10.1021/bc00001a009 *
GUO, JIANFENG ET AL.: "Biomimetic Gold Nanocomplexes for Gene Knockdown: Will Gold Deliver Dividends for Small Interfering RNA Nanomedicines?", NANO RESEARCH, vol. 8, no. 10, 2015, pages 3111 - 3140, XP035554714, DOI: doi:10.1007/s12274-015-0829-4 *

Also Published As

Publication number Publication date
KR20180099072A (ko) 2018-09-05
WO2018159990A2 (fr) 2018-09-07
KR101992401B1 (ko) 2019-06-24

Similar Documents

Publication Publication Date Title
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
CY1123642T1 (el) Αντισωματα enanti-pd-1
CL2019000966A1 (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones, y procesos, relacionados a las mismas.
MA49034B1 (fr) Anticorps anti-lag3
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
BR112016029040A2 (pt) método de uso de um composto quaternário de amônia, um polissacarídeo catiônico e um polissacarídeo não iônico
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112015029254A2 (pt) composição detergente de baixo ph compreendendo tensoativos não iônicos
EA201190196A1 (ru) Магнитные гидрофобные агломераты
WO2018194496A3 (fr) Anticorps monoclonal à pd-l1
EA201992027A1 (ru) Водный состав антитела против pd-l1
WO2017135791A8 (fr) Anticorps anti-cmet et leurs utilisations
WO2018101663A3 (fr) Composition pour l'élimination de tissu biologique et procédé d'élimination de tissu biologique l'utilisant
MX2016011530A (es) Mejoras en o con relacion a compuestos organicos.
DOP2017000193A (es) Composición ácida a base de leonardita y aminoácidos
MX2021007245A (es) Microorganismos para la produccion de putrescina u ornitina y procedimiento para la produccion de putrescina u ornitina usando los mismos.
GT201400073A (es) Pesticidas heterociclicos sustituidos con 1,3-diarilo
WO2019027173A3 (fr) Nouvelle psicose-6-phosphate phosphatase, composition pour la production de psicose comprenant ladite enzyme, procédé pour la production de psicose au moyen de ladite enzyme
EA201300138A1 (ru) Фармацевтическая композиция и метод ингибирования продукции или усиления элиминации белка p24
LT2013016A (lt) Aktyvuotos-potencijuotos formos antikūno poveikio padidinimo būdas
EA201791716A1 (ru) Фармацевтический состав
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
RS54777B1 (sr) Postupak za biološku borbu protiv pseudomonas
UA114082C2 (xx) Спосіб одержання водорозчинних селеноглікопротеїнів та композиція, що їх містить
BR112019007795A2 (pt) pó de tratamento de superfície ativado pela umidade ambiente

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18761256

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18761256

Country of ref document: EP

Kind code of ref document: A2